KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Gains from Investment Securities (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Gains from Investment Securities for 7 consecutive years, with $900000.0 as the latest value for Q3 2025.

  • Quarterly Gains from Investment Securities rose 80.0% to $900000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, up 197.47% year-over-year, with the annual reading at $8.9 million for FY2025, 538.74% up from the prior year.
  • Gains from Investment Securities hit $900000.0 in Q3 2025 for Royalty Pharma, up from $600000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $16.3 million in Q1 2023 to a low of -$13.0 million in Q4 2024.
  • Historically, Gains from Investment Securities has averaged $3.0 million across 5 years, with a median of $3.0 million in 2022.
  • Biggest five-year swings in Gains from Investment Securities: surged 522.54% in 2021 and later plummeted 195.91% in 2023.
  • Year by year, Gains from Investment Securities stood at $6.5 million in 2021, then grew by 4.76% to $6.8 million in 2022, then tumbled by 195.91% to -$6.6 million in 2023, then plummeted by 97.9% to -$13.0 million in 2024, then soared by 106.93% to $900000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for RPRX at $900000.0 in Q3 2025, $600000.0 in Q2 2025, and -$13.0 million in Q4 2024.